BRAEGEN PHARMACEUTICAL
Braegen Pharmaceutical Company, is based in China. The company is developing drugs for neurodegenerative diseases including Alzheimer’s disease. The Emory intellectual property licensed to the company relates to a series of small molecule precursors to7, 8-dihydroxyflavone (7, 8 DHF), a potent tyrosine receptor kinase B (TrkB) agonist, for the treatment of various neurological diseases.
BRAEGEN PHARMACEUTICAL
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Atlanta, Georgia, United States
Country:
United States
Status:
Active
Similar Organizations
Neuromagen Pharma
Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.
Synaps Dx
Synaps Dx focuses on the research, development and commercialization for neurodegenerative disorders including Alzheimer’s Disease.
More informations about "Braegen Pharmaceutical"
Braegen 2025 Company Profile: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Braegen. Use the PitchBook Platform to explore the full profile.See details»
Braegen Pharmaceutical Co. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Explore Braegen Pharmaceutical Co. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Endocrinology and Metabolic Disease, Nervous …See details»
Shenzhen Boruijian Pharmaceutical Co. Ltd. (Braegen …
Shenzhen Boruijian Pharmaceutical Co. Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
BrAD-R13 - Drug Targets, Indications, Patents - Synapse
6 days ago BrAD-R13: a TrkB stimulants Drug, Initially developed by Braegen Pharmaceutical Co., Now, its global highest R&D status is Phase 1, Mechanism: TrkB stimulants (Neurotrophic …See details»
braegen.com.cn - 博芮健制药
Innovation makes Life Better 创新 · 突破 · 专注 · 感恩 关于我们 深圳博芮健制药有限公司 (Braegen Pharmaceutical) What We Are 我们是一家以创新研究为基础、以市场需求为导向、以推进人类健康事业为使命的新药研发企业。See details»
Braegen-03 - Drug Targets, Indications, Patents - Synapse
Braegen-03: a LGMN inhibitors Drug, Initially developed by Shanghai Braegen Pharmaceuticals, Now, its global highest R&D status is Preclinical, Mechanism: LGMN inhibitors (legumain …See details»
Braegen Pharmaceutical Co. (Braegen Pharmaceutical Co.) - 药物 …
了解Braegen Pharmaceutical Co. (Braegen Pharmaceutical Co.)公司的药物管线，治疗领域，技术平台，以及它的，疾病领域:内分泌与代谢疾病，神经系统疾病，技术平台:小分子化药，药 …See details»
BG大游· (中国)集团
创新 · 突破 · 专注 · 感恩 BG大游官网 深圳BG大游官网制药有限公司 (Braegen Pharmaceutical) What We Are 我们是一家以创新研究为基础、以市场需求为导向、以推进人类健康事业为使命 …See details»
Braegen Pharmaceuticals - Growth Outlook - Crunchbase
Braegen Pharmaceuticals is a novel medicine development and research organization focused on cutting-edge research.See details»
Braegen Pharmaceuticals - Funding, Financials, Valuation & Investors
Nov 19, 2024 Braegen Pharmaceuticals is a novel medicine development and research organization focused on cutting-edge research.See details»
18F CP6A - AdisInsight
At a glance Originator Braegen Pharmaceutical Class Diagnostic agents; Imaging agents Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging …See details»
BrAD-R13: Drug Targets, Indications, Patents - Synapse
BrAD-R13: a TrkB stimulants Drug, Initially developed by Braegen Pharmaceutical Co., Now, its global highest R&D status is Phase 1, Mechanism: TrkB stimulants (Neurotrophic tyrosine …See details»
Braegen Pharmaceuticals - Financial Details - Crunchbase
Braegen Pharmaceuticals is a novel medicine development and research organization focused on cutting-edge research.See details»
Shenzhen Boruijian Pharmaceutical Co., Ltd. (深圳博芮健制药有限 …
Jun 1, 2025 了解Shenzhen Boruijian Pharmaceutical Co., Ltd. (深圳博芮健制药有限公司)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 16篇新闻，疾病领域:神经系统疾 …See details»
Biogen beefs up North Carolina manufacturing ahead of potential …
10 hours ago Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as it seeks to expand in the U.S. amid President …See details»
Shenzhen Boruijian Pharmaceutical Co., Ltd. - Drug pipelines, …
Jun 1, 2025 Explore Shenzhen Boruijian Pharmaceutical Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, Disease Domain:Nervous System ...See details»
Braegen-05 - Drug Targets, Indications, Patents - Synapse
May 7, 2025 Braegen-05: a α-synuclein modulators Drug, Initially developed by Shenzhen Boruijian Pharmaceutical Co., Ltd., Now, its global highest R&D status is Phase 1, …See details»
Braegen Pharmaceuticals - Crunchbase
Braegen Pharmaceuticals is a novel medicine development and research organization focused on cutting-edge research.See details»
Braegen Pharmaceuticals - Profiles & Contacts - Crunchbase
Braegen Pharmaceuticals is a novel medicine development and research organization focused on cutting-edge research.See details»
Braegen-03 - Drug Targets, Indications, Patents - Synapse
Braegen-03: a LGMN inhibitors Drug, Initially developed by Shenzhen Boruijian Pharmaceutical Co., Ltd., Now, its global highest R&D status is Preclinical, Mechanism: LGMN inhibitors …See details»